The Clinical Significance of Erythrocytic Macrocytosis in Metastatic Renal Cell Cancer and Sarcoma Patients Treated with Pazopanib

Yusuf İlhan; Mehmet Fatih Özbay; Sema Sezgin Göksu; Ali Murat Tatlı; Hasan Şenol Coşkun

Article Details

The Clinical Significance of Erythrocytic Macrocytosis in Metastatic Renal Cell Cancer and Sarcoma Patients Treated with Pazopanib

Authors:

Yusuf İlhan | Mehmet Fatih Özbay | Sema Sezgin Göksu | Ali Murat Tatlı | Hasan Şenol Coşkun

Publisher:

Akdeniz University

Main Topics:

Klinik Tıp Bilimleri

Journal:

Akdeniz Tıp Dergisi Vol.10 Issue 1, pp.131-136

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001309837

pISSN:

2687-2781

Keywords:

Abstract:

 Objective: Pazopanib is a multi-kinase inhibitor used in metastatic renal cell carcinoma or sarcomas mRCC or mSTS. We aimed to investigate the relationship between pazopanib and macrocytosis and evaluate the clinical significant of this effect in mRCC or mSTS. Methods: Patients diagnosed with mRCC and mSTS and have been treated with pazopanib were included. Drug-induced macrocytosis was defined as MCV 100 fL during any mount of treatment. ΔMCV was defined as difference between MCV during pazopanib treatment and baseline MCV. Data was collected retrospectively. Results: 50 patients were included the study. During the pazopanib treatment, significant increase in MCV levels was observed and the mean MCV at the 0, 1, 3, 6, and 9 months were found as 86.77.6 fL, 87.8  7.5, 92.4  8.9, 94.8  11.1 and 99.0  10.7 fL, retrospectively p0.001. In the group with ΔMCV3  5fL, median PFS was found 48.0 months 95 CI, 26.3-69.9; in the group with ΔMCV3 5, it was 25 months 95 CI, 14.6-35.4 p:0.036. Median PFS was 21.0 months 95 CI, 0-46.3 for macrocytic patients compared to 4.0 months 95 CI, 2.0-5.9 in normocytic patients p:0.023.There was no statistically significant difference between the groups for overall survival. Conclusion: A significant increases in MCV values or the development of macrocytosis during the pazopanib treatment in mRCC and mSTS, can be used as an important biomarker for progression-free survival.

 Objective: Pazopanib is a multi-kinase inhibitor used in metastatic renal cell carcinoma or sarcomas mRCC or mSTS. We aimed to investigate the relationship between pazopanib and macrocytosis and evaluate the clinical significant of this effect in mRCC or mSTS. Methods: Patients diagnosed with mRCC and mSTS and have been treated with pazopanib were included. Drug-induced macrocytosis was defined as MCV 100 fL during any mount of treatment. ΔMCV was defined as difference between MCV during pazopanib treatment and baseline MCV. Data was collected retrospectively. Results: 50 patients were included the study. During the pazopanib treatment, significant increase in MCV levels was observed and the mean MCV at the 0, 1, 3, 6, and 9 months were found as 86.77.6 fL, 87.8  7.5, 92.4  8.9, 94.8  11.1 and 99.0  10.7 fL, retrospectively p0.001. In the group with ΔMCV3  5fL, median PFS was found 48.0 months 95 CI, 26.3-69.9; in the group with ΔMCV3 5, it was 25 months 95 CI, 14.6-35.4 p:0.036. Median PFS was 21.0 months 95 CI, 0-46.3 for macrocytic patients compared to 4.0 months 95 CI, 2.0-5.9 in normocytic patients p:0.023.There was no statistically significant difference between the groups for overall survival. Conclusion: A significant increases in MCV values or the development of macrocytosis during the pazopanib treatment in mRCC and mSTS, can be used as an important biomarker for progression-free survival.

 Objective: Pazopanib is a multi-kinase inhibitor used in metastatic renal cell carcinoma or sarcomas mRCC or mSTS. We aimed to investigate the relationship between pazopanib and macrocytosis and evaluate the clinical significant of this effect in mRCC or mSTS. Methods: Patients diagnosed with mRCC and mSTS and have been treated with pazopanib were included. Drug-induced macrocytosis was defined as MCV 100 fL during any mount of treatment. ΔMCV was defined as difference between MCV during pazopanib treatment and baseline MCV. Data was collected retrospectively. Results: 50 patients were included the study. During the pazopanib treatment, significant increase in MCV levels was observed and the mean MCV at the 0, 1, 3, 6, and 9 months were found as 86.77.6 fL, 87.8  7.5, 92.4  8.9, 94.8  11.1 and 99.0  10.7 fL, retrospectively p0.001. In the group with ΔMCV3  5fL, median PFS was found 48.0 months 95 CI, 26.3-69.9; in the group with ΔMCV3 5, it was 25 months 95 CI, 14.6-35.4 p:0.036. Median PFS was 21.0 months 95 CI, 0-46.3 for macrocytic patients compared to 4.0 months 95 CI, 2.0-5.9 in normocytic patients p:0.023.There was no statistically significant difference between the groups for overall survival. Conclusion: A significant increases in MCV values or the development of macrocytosis during the pazopanib treatment in mRCC and mSTS, can be used as an important biomarker for progression-free survival.

 Amaç: Pazopanib, metastatik renal hücreli karsinom mRHK ve metastatik yumuşak doku kanserlerinde mYDK kullanılan multi-kinaz inhibitörüdür. Çalışmamızda pazopanib tedavisinin ortalama eritrosit hacmi MCV üzerine etkisinin ve progresyonsuz sağkalım süresi PSS ve genel sağkalım süresi GSS üzerine etkilerinin incelenmesi amaçlanmıştır. Yöntem: Çalışmamız tek merkezli, retrospektif olarak planlandı ve mRHK veya mYDK tanılı ve pazopanib kullanan hastalar dahil edilmiştir. ΔMCV, tedavinin belli bir ayındaki MCV ile başlangıç MCV arasındaki fark; makrositoz ise tedavinin herhangi bir ayında MCV 100 fL olarak tanımlanmıştır. MCV artışı ve makrositoz ile sağkalım ilişkisi istatiksel olarak analiz edilmiştir. Bulgular: Hasta sayısı 50 idi. Pazopanib ile 0.ay, 1.ay, 3.ay, 6.ay ve 9.ay ortalama MCV değerleri sırasıyla 86,7  7,6, 87,8  7,5, 92,4  8,9, 94,8  11,1 ve 99,0  10,7 fL olarak hesaplandı p0,001. Yirmi iki hastanın 44 üçüncü MCVsi 5 fL ve üzeri artmış olarak bulundu. Hastaların 14 ünde 28 makrositoz gelişti. Üçüncü ayda ΔMCV 5 fL ve üstü olanların mPSS 48.0 ay 95 CI, 26.3-69.9 iken; 5in altı olanlarda mPSS 25 ay 95 CI, 14.6-35.4 olarak bulundu p:0.036. Makrositoz olmayan hastalarda mPSS 4.0 ay iken 95 CI, 2.0-5.9; makrositoz gelişen hastalarda mPSS 21.0 ay 95 CI, 0-46.3 olarak bulundu p: 0.023. ΔMCV ve makrositoz gelişimi ile GSS arasında istatiksel anlamlı bir fark bulunmadı. Sonuç: Pazopanib ile tedavi edilen mRHK ve mYDK de, MCV değerlerindeki anlamlı artışın veya makrositoz gelişiminin, prospektif çalışmalar ile valide edildiği takdirde önemli bir gösterge olabileceğini düşünmekteyiz.

Article Details

The Clinical Significance of Erythrocytic Macrocytosis in Metastatic Renal Cell Cancer and Sarcoma Patients Treated with Pazopanib

Authors:

Yusuf İlhan | Mehmet Fatih Özbay | Sema Sezgin Göksu | Ali Murat Tatlı | Hasan Şenol Coşkun

Publisher:

Akdeniz University

Main Topics:

Klinik Tıp Bilimleri

Journal:

Akdeniz Tıp Dergisi Vol.10 Issue 1, pp.131-136

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001309837

pISSN:

2687-2781

Mean Corpuscular Volume (MCV)

Macrocytosis

Pazopanib

Progression-free SurvivalOrtalama eritrosit hacmi (MCV)

Makrositoz

Pazopanib

Progresyonsuz Sağkalım

Issues

Article Details

Authors: Yusuf İlhan | Mehmet Fatih Özbay | Sema Sezgin Göksu | Ali Murat Tatlı | Hasan Şenol Coşkun

Publisher: Akdeniz University

Main Topics: Klinik Tıp Bilimleri

Journal: Akdeniz Tıp Dergisi Vol.10 Issue 1, pp.131-136

Document Type: Article

Publication Date: 1/2024

Document Language: English

Document ID (Org No.): 2001309837

pISSN: 2687-2781

Issues

Authors:

Yusuf İlhan | Mehmet Fatih Özbay | Sema Sezgin Göksu | Ali Murat Tatlı | Hasan Şenol Coşkun

Publisher:

Akdeniz University

Main Topics:

Klinik Tıp Bilimleri

Journal:

Akdeniz Tıp Dergisi Vol.10 Issue 1, pp.131-136

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001309837

pISSN:

2687-2781